Test-retest Evaluation of [18F]F-AraG PET

Recruiting now · Phase 2

Conditions studied: Non-small Cell Lung Cancer

In brief

This pilot study aims to evaluate the test-retest variability of \[18F\]F-AraG-PET imaging in patients with advanced NSCLC tumors. The main objectives of the study are to quantify the uptake of \[18F\]F-AraG in tumors and lymphoid tissue in two consecutive scans spaced not longer than 7 days apart from each other to estimate the magnitude of physiologic and measurement variability. To explore these objectives, eligible subjects will undergo two \[18F\]F-AraG PET/CT scans within 7 days of each other prior to receiving treatment. This study is a single-site, open-label, non-randomized, single-arm pilot trial. Patients and care providers will not be blinded to any part of the study.

Key facts

Study ID

NCT06084806

Run by

CellSight Technologies, Inc.

People needed

10

Starts

2023-10-31

Expected to finish

2025-10-31

Last updated by the study team

2024-10-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients (>18 years old) with a histologically confirmed NSCLC and a candidate to receive immunotherapy as monotherapy or as combination therapy for advanced/metastatic disease.
• Measurable disease.
• ECOG performance status of 0, 1 or 2.

You may not qualify if…

• Serious comorbidities that in the opinion of the investigator/sponsor could compromise protocol objectives.
• Pregnant women or nursing mothers.
• Patients with severe claustrophobia.

Where it is running

• University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.